We are live on ! Find out more
BC

Boxer Capital Portfolio holdings

AUM $2.04B
1-Year Est. Return 108.39%
This Fund
S&P 500
This Quarter Est. Return
+5.57%
1 Year Est. Return
+108.39%
3 Year Est. Return
+261.8%
5 Year Est. Return
+1,135.09%
10 Year Est. Return
–
AUM
$1.88B
AUM Growth
-$278M
Cap. Flow
-$105M
Cap. Flow %
-5.61%
Top 10 Hldgs %
47.5%
Holding
84
New
5
Increased
6
Reduced
10
Closed
11

Top Buys

Rank Stock Value
1
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$42.9M
2
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$39.9M
3
PRTA icon
Prothena Corp
PRTA
+$19.3M
4
IMVT icon
Immunovant
IMVT
+$17M
5
ABOS icon
Acumen Pharmaceuticals
ABOS
+$13.6M

Top Sells

Rank Stock Value
1
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
+$146M
2
ETNB
89bio
ETNB
+$39.8M
3
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$32.5M
4
CABA icon
Cabaletta Bio
CABA
+$6.97M
5
IRON icon
Disc Medicine
IRON
+$5.77M

Sector Composition

Rank Sector Weight
1 Healthcare 98.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MRTX
1
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$139M 7.42%
3,201,440
+1,201,440
+60% +$42.9M
RVMD icon
2
Revolution Medicines
RVMD
$39.9B
$130M 6.9%
4,684,264
– –
ONC
3
BeOne Medicines Ltd
ONC
$32.8B
$89.9M 4.79%
500,000
– –
TYRA icon
4
Tyra Biosciences
TYRA
$1.9B
$88.8M 4.73%
6,448,359
– –
AKRO
5
DELISTED
Akero Therapeutics
AKRO
$84.8M 4.51%
1,676,733
– –
TNGX icon
6
Tango Therapeutics
TNGX
$4.43B
$80.2M 4.27%
7,123,642
– –
SWTX
7
DELISTED
SpringWorks Therapeutics
SWTX
$79.1M 4.21%
3,421,541
– –
SRPT icon
8
Sarepta Therapeutics
SRPT
$1.57B
$72.7M 3.87%
600,000
– –
APLS
9
DELISTED
Apellis Pharmaceuticals
APLS
$65.7M 3.5%
1,726,000
+150,000
+10% +$6.59M
CYTK icon
10
Cytokinetics
CYTK
$10.5B
$61.9M 3.29%
2,100,000
– –
IDYA icon
11
IDEAYA Biosciences
IDYA
$3.42B
$59.4M 3.16%
2,202,812
– –
NUVL
12
DELISTED
Nuvalent
NUVL
$55.6M 2.96%
1,210,192
– –
IMGN
13
DELISTED
Immunogen Inc
IMGN
$47M 2.5%
2,961,000
– –
MRUS
14
DELISTED
Merus
MRUS
$44.8M 2.39%
1,900,000
– –
KRTX
15
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$42.3M 2.25%
250,000
– –
ARGX icon
16
argenx
ARGX
$53.4B
$41.8M 2.22%
85,000
+10,000
+13% +$4.89M
LEGN icon
17
Legend Biotech
LEGN
$3.59B
$40.3M 2.15%
600,000
– –
AMLX icon
18
Amylyx Pharmaceuticals
AMLX
$2.26B
$38.2M 2.03%
2,084,000
– –
XBI icon
19
State Street SPDR S&P Biotech ETF
XBI
$9.95B
$36.5M 1.94%
+500,000
New +$39.9M
PRTA icon
20
Prothena Corp
PRTA
$425M
$30.2M 1.61%
625,000
+325,000
+108% +$19.3M
RCKT icon
21
Rocket Pharmaceuticals
RCKT
$340M
$30M 1.6%
1,466,051
– –
VTYX
22
DELISTED
Ventyx Biosciences
VTYX
$29.5M 1.57%
850,000
– –
IMVT icon
23
Immunovant
IMVT
$7.93B
$28.8M 1.53%
+750,000
New +$17M
RCUS icon
24
Arcus Biosciences
RCUS
$3.55B
$28.8M 1.53%
1,602,200
– –
FOLD
25
DELISTED
Amicus Therapeutics
FOLD
$28.3M 1.51%
2,325,000
– –
1
2 3 4

Similar funds

FTDI
First Trust Direct Indexing Boston, Massachusetts $1.87B AUM 43.63% 1-Year Est. Return
CIM
Contrarius Investment Management St. Helier, Jersey $1.76B AUM 35.87% 1-Year Est. Return
PRO
Pensioenfonds Rail & OV Utrecht, Netherlands $1.44B AUM 23.73% 1-Year Est. Return
GFS
GYL Financial Synergies West Hartford, Connecticut $1.33B AUM 34.46% 1-Year Est. Return
ECM
Ensemble Capital Management San Francisco, California $1.18B AUM 41.81% 1-Year Est. Return
CIP
Chartwell Investment Partners Berywn, Pennsylvania $2.91B AUM 40.48% 1-Year Est. Return
SEC
Seven Eight Capital New York $1.11B AUM 29.48% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Boxer Capital's Q3 2023 Portfolio in Review

As of Q3 2023, Boxer Capital held 84 positions worth $1.88B, down 13% from $2.16B the previous quarter. Its ten largest holdings account for 47% of the portfolio.

Boxer Capital withdrew a net $105M in Q3 2023, closing 11 positions and reducing 10 holdings. Its most notable exit was Reata Pharmaceuticals, Inc. Class A Common Stock, an estimated $146M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 100% a quarter earlier.

Against the trend, Boxer Capital opened a new position in State Street SPDR S&P Biotech ETF worth $36.5M.

  • Boxer Capital's largest Q3 2023 buy was State Street SPDR S&P Biotech ETF: 500,000 shares worth $36.5M.
  • Boxer Capital added most to Mirati Therapeutics, Inc. Common Stock in Q3 2023, an estimated $42.9M increase.
  • Boxer Capital's biggest Q3 2023 reduction was Black Diamond Therapeutics, cutting an estimated $5.56M.
  • Boxer Capital fully exited Reata Pharmaceuticals, Inc. Class A Common Stock in Q3 2023, selling an estimated $146M.
  • Boxer Capital's ten largest holdings make up 47% of its $1.88B portfolio in Q3 2023.
  • Boxer Capital opened 5 new positions and closed 11 in Q3 2023.
  • Boxer Capital's portfolio value fell 13% quarter-over-quarter to $1.88B.

Based on Boxer Capital's 13F filing for Q3 2023, filed 14 Nov 2023.